Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma.

Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM.

Breast Cancer Res. 2011 May 18;13(3):R51. doi: 10.1186/bcr2882.

2.

Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.

Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, Harrison DJ.

J Vis Exp. 2011 Oct 25;(56):e3334. doi: 10.3791/3334.

3.

Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.

Fuqua SA, Cui Y.

Breast Cancer Res Treat. 2004;87 Suppl 1:S3-10.

PMID:
15597215
4.

Biomarker research in breast cancer.

Maxwell C.

Clin J Oncol Nurs. 2010 Dec;14(6):771-83. doi: 10.1188/10.CJON.771-783.

PMID:
21112854
5.

Age-associated biomarker profiles of human breast cancer.

Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC.

Int J Biochem Cell Biol. 2002 Nov;34(11):1318-30.

PMID:
12200028
6.

Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.

Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG.

Cancer Invest. 2007 Feb;25(1):19-26.

PMID:
17364553
7.

Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.

Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, Trivedi TI.

Ann Surg Oncol. 2000 May;7(4):305-11.

PMID:
10819372
9.
10.

Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, Boudawara T.

World J Surg Oncol. 2008 Oct 22;6:112. doi: 10.1186/1477-7819-6-112.

11.

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

J Clin Pathol. 2007 Apr;60(4):397-404. Epub 2006 Jun 14.

12.

Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.

Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL.

Cancer Res. 2006 May 15;66(10):5487-94.

13.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
14.

Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.

Shin BK, Lee Y, Lee JB, Kim HK, Lee JB, Cho SJ, Kim A.

Oncol Rep. 2008 Mar;19(3):617-25.

PMID:
18288392
15.

Estrogenic microenvironment generated by organochlorine residues in adipose mammary tissue modulates biomarker expression in ERalpha-positive breast carcinomas.

Muñoz-de-Toro M, Durando M, Beldoménico PM, Beldoménico HR, Kass L, García SR, Luque EH.

Breast Cancer Res. 2006;8(4):R47.

16.

Current issues in ER and HER2 testing by IHC in breast cancer.

Gown AM.

Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34. Review.

17.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

18.

Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.

Fabian CJ, Kamel S, Zalles C, Kimler BF.

J Cell Biochem Suppl. 1996;25:112-22.

PMID:
9027607
19.

LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.

Liu D, Baltayan A, Naritoku WY, Barr NJ, Young LL, Chaiwun B, Tsao-Wei DD, Groshen SL, Taylor CR, Torloni H, Neville AM, Cote RJ, Imam SA.

Anticancer Res. 2000 May-Jun;20(3A):1451-61.

PMID:
10928056
20.

Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.

Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C.

Diagn Mol Pathol. 2011 Mar;20(1):1-10. doi: 10.1097/PDM.0b013e3181e3630c.

PMID:
21326033

Supplemental Content

Support Center